The global PEGylated proteins market accounted for USD 1.53 billion in 2023 and is expected to reach USD 5.20 billion by 2034 with a CAGR of 11.76% during the forecast period 2024-2034. Growing the number of new product releases and regulatory authority approvals, growing incidence of long-term illnesses, and growing preference for protein-based medications over small molecule medications, the market expansion will be fueled by rising R&D expenditures from biotechnology and pharmaceutical businesses as well as technological developments in PEGylation methods.
Small molecule medications lack some of the benefits that protein-based medications have to offer, such as increased potency and target specificity. Protein-based medications' pharmacokinetic qualities can be improved through PEGylation, which increases their therapeutic potential even further. For instance, in February 2024, Merck reported favorable outcomes from a Phase 3 trial using their experimental PEGylated glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrating notable drops in blood sugar levels in type 2 diabetic patients.
By product, the consumables segment accounted for the highest revenue-grossing segment in the global PEGylated proteins market in 2023 owing to the increased demand for PEGylation reagents, purification kits, and other supplies essential for the production and development of PEGylated protein therapeutics. For instance, in October 2023, Amgen reported favorable outcomes from a Phase 1 trial involving patients with advanced solid tumors and the PEGylated interleukin-10 (IL-10) inhibitor AMG 810. Additionally, the services segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising outsourcing of PEGylation process development, analytical testing, and contract manufacturing services by biopharmaceutical companies seeking to streamline operations and accelerate product development timelines.
By protein type, the monoclonal antibodies segment accounted for the highest revenue-grossing segment in the global PEGylated proteins market in 2023 owing to the increasing adoption of PEGylated monoclonal antibodies in the treatment of cancer, autoimmune diseases, and other therapeutic areas, driven by their enhanced pharmacokinetic properties and targeted therapeutic effects. For instance, in February 2022, Merck KGaA paid $780 million to acquire Exelead, a CDMO that specializes in PEGylated pharmaceuticals. The purpose of this acquisition was to increase Merck KGaA's presence in PEGylated pharmaceuticals and enhance its mRNA and lipid capabilities. Additionally, the colony-stimulating factors segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for PEGylated colony-stimulating factors in the treatment of chemotherapy-induced neutropenia and other hematological disorders, supported by their prolonged half-life and improved efficacy compared to conventional formulations.
By application, the cancer treatment segment accounted for the highest revenue-grossing segment in the global PEGylated proteins market in 2023 owing to the increased adoption of PEGylated protein-based therapies for targeted cancer treatment, leveraging their enhanced pharmacokinetic properties and reduced immunogenicity to improve patient outcomes and quality of life. For instance, in July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of doxorubicin hydrochloride (Celdoxome pegylated liposomal) for the treatment of AIDS-related Kaposi's sarcoma, progressive multiple myeloma, metastatic breast cancer, and advanced ovarian cancer. Additionally, the autoimmune diseases segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of autoimmune diseases and the expanding therapeutic applications of PEGylated proteins in managing autoimmune disorders, driving increased research and development efforts and clinical adoption.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global PEGylated proteins market in 2023 owing to the increased investment in research and development of PEGylated protein therapeutics by pharmaceutical and biotechnology companies, aimed at addressing unmet medical needs and expanding their product portfolios. For instance, in March 2022, Flow Eighteen38, a division of the protein sciences created to help and expedite antibody characterization and protein purification projects, announced that its parent company, CRO FairJourneyBiologics S.A., would invest EUR 5 million (USD 5.58 million) in the company's protein production and biophysical characterization capabilities and services. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for outsourcing of PEGylation process development, analytical testing, and manufacturing services by pharmaceutical and biotechnology companies to streamline operations and accelerate drug development timelines.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a well-established biopharmaceutical industry, favorable regulatory environment, high healthcare expenditure, and increasing adoption of PEGylated protein therapeutics for various disease indications. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing prevalence of chronic diseases, rising investment in biotechnology and pharmaceutical research, and growing adoption of PEGylated protein therapeutics across the region. For instance, in July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of doxorubicin hydrochloride, also known as Celdoxome pegylated liposomal, based on a favorable opinion. Patients with metastatic breast cancer, AIDS-related Kaposi's sarcoma, progressive multiple myeloma, and advanced ovarian cancer are the indicated uses of this medicine.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Small molecule medications lack some of the benefits that protein-based medications have to offer, such as increased potency and target specificity. Protein-based medications' pharmacokinetic qualities can be improved through PEGylation, which increases their therapeutic potential even further. For instance, in February 2024, Merck reported favorable outcomes from a Phase 3 trial using their experimental PEGylated glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrating notable drops in blood sugar levels in type 2 diabetic patients.
By product, the consumables segment accounted for the highest revenue-grossing segment in the global PEGylated proteins market in 2023 owing to the increased demand for PEGylation reagents, purification kits, and other supplies essential for the production and development of PEGylated protein therapeutics. For instance, in October 2023, Amgen reported favorable outcomes from a Phase 1 trial involving patients with advanced solid tumors and the PEGylated interleukin-10 (IL-10) inhibitor AMG 810. Additionally, the services segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising outsourcing of PEGylation process development, analytical testing, and contract manufacturing services by biopharmaceutical companies seeking to streamline operations and accelerate product development timelines.
By protein type, the monoclonal antibodies segment accounted for the highest revenue-grossing segment in the global PEGylated proteins market in 2023 owing to the increasing adoption of PEGylated monoclonal antibodies in the treatment of cancer, autoimmune diseases, and other therapeutic areas, driven by their enhanced pharmacokinetic properties and targeted therapeutic effects. For instance, in February 2022, Merck KGaA paid $780 million to acquire Exelead, a CDMO that specializes in PEGylated pharmaceuticals. The purpose of this acquisition was to increase Merck KGaA's presence in PEGylated pharmaceuticals and enhance its mRNA and lipid capabilities. Additionally, the colony-stimulating factors segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for PEGylated colony-stimulating factors in the treatment of chemotherapy-induced neutropenia and other hematological disorders, supported by their prolonged half-life and improved efficacy compared to conventional formulations.
By application, the cancer treatment segment accounted for the highest revenue-grossing segment in the global PEGylated proteins market in 2023 owing to the increased adoption of PEGylated protein-based therapies for targeted cancer treatment, leveraging their enhanced pharmacokinetic properties and reduced immunogenicity to improve patient outcomes and quality of life. For instance, in July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of doxorubicin hydrochloride (Celdoxome pegylated liposomal) for the treatment of AIDS-related Kaposi's sarcoma, progressive multiple myeloma, metastatic breast cancer, and advanced ovarian cancer. Additionally, the autoimmune diseases segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing prevalence of autoimmune diseases and the expanding therapeutic applications of PEGylated proteins in managing autoimmune disorders, driving increased research and development efforts and clinical adoption.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global PEGylated proteins market in 2023 owing to the increased investment in research and development of PEGylated protein therapeutics by pharmaceutical and biotechnology companies, aimed at addressing unmet medical needs and expanding their product portfolios. For instance, in March 2022, Flow Eighteen38, a division of the protein sciences created to help and expedite antibody characterization and protein purification projects, announced that its parent company, CRO FairJourneyBiologics S.A., would invest EUR 5 million (USD 5.58 million) in the company's protein production and biophysical characterization capabilities and services. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for outsourcing of PEGylation process development, analytical testing, and manufacturing services by pharmaceutical and biotechnology companies to streamline operations and accelerate drug development timelines.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a well-established biopharmaceutical industry, favorable regulatory environment, high healthcare expenditure, and increasing adoption of PEGylated protein therapeutics for various disease indications. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing prevalence of chronic diseases, rising investment in biotechnology and pharmaceutical research, and growing adoption of PEGylated protein therapeutics across the region. For instance, in July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of doxorubicin hydrochloride, also known as Celdoxome pegylated liposomal, based on a favorable opinion. Patients with metastatic breast cancer, AIDS-related Kaposi's sarcoma, progressive multiple myeloma, and advanced ovarian cancer are the indicated uses of this medicine.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Protein Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: PEGylated Proteins Market Report 2023 - 2034
PEGylated Proteins Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Consumable
- PEGylation Kits and Reagents
- Monofunctional Linear PEGs
- Bifunctional PEGs
- Services
- Other Product Types
- Colony-stimulating Factor
- Interferons
- Erythropoietin
- Recombinant Factor VII
- Others
PEGylated Proteins Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cancer
- Autoimmune Diseases
- Hepatitis
- Multiple Sclerosis
- Hemophilia
- Gastrointestinal Disorders
- Others
PEGylated Proteins Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academic & Research Institutes
PEGylated Proteins Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. PEGylated Proteins Market: Product Estimates & Trend Analysis
8. PEGylated Proteins Market: Protein Type Estimates & Trend Analysis
9. PEGylated Proteins Market: Application Estimates & Trend Analysis
10. PEGylated Proteins Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America PEGylated Proteins Market
13. Europe Global PEGylated Proteins Market
14. Asia Pacific Global PEGylated Proteins Market
15. Latin America Global PEGylated Proteins Market
16. MEA Global PEGylated Proteins Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Merck & Co. Inc.
- Roche Holding AG
- Pfizer Inc.
- Novo Nordisk A/S
- Amgen Inc.
- Biogen Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Celgene Corporation (a subsidiary of Bristol Myers Squibb)
- AbbVie Inc.
- Johnson & Johnson
- CSL Limited
- Teva Pharmaceutical Industries Ltd.
- Lonza Group AG
- Dr. Reddy's Laboratories Ltd.
